Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nexa's pyrolytic thumb implant:

This article was originally published in Clinica

Executive Summary

Nexa Orthopedics has received US FDA 510(k) clearance to sell its pyrolytic carbon carpometacarpal implant (CMI) for relieving basal thumb joint pain associated with arthritis, while improving the thumb's range of motion and biomechanical function. The San Diego, California firm added the product to its portfolio following its recent acquisition of BioProfile, which according to Nexa, has been marketing products in Europe for "many years". Nexa claims to be the only company in the world that designs, manufactures and distributes orthopaedic implants made of pyrolytic carbon. The CMI's official US launch is scheduled to take place in September 2006 at the American Society for Surgery of the Hand meeting, in Washington, DC.

You may also be interested in...

Health And Wellness Trademark Review 1 December, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Ipsen CEO Outlines Strategy For Long-Term Success

While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.

US Startup Ignites Consumer Health Portfolio Build With North American Rights To ThermaCare

Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts